Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal Phase 3 trial. Prometic Life Sciences Inc. announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no…